Leads from the MMWR. Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum.
D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004351:Drug Resistance; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000187:drug effects; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use; D013413:Sulfadoxine / Q000009:adverse effects / Q000627:therapeutic use; D014195:Travel
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine